WallStreetZenWallStreetZen

NASDAQ: INAB
In8bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INAB

Based on 1 analyst offering 12 month price targets for In8bio Inc

Min Forecast
$6.00+316.67%
Avg Forecast
$6.00+316.67%
Max Forecast
$6.00+316.67%

Should I buy or sell INAB stock?

Based on 1 analyst offering ratings for In8bio Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their INAB stock forecasts and price targets.

INAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-13

1 of 1

Forecast return on equity

Is INAB forecast to generate an efficient return?

Company
-58.5%
Industry
69.51%
Market
178.05%
INAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INAB forecast to generate an efficient return on assets?

Company
-49.94%
Industry
31.92%
INAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INAB earnings per share forecast

What is INAB's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.75
Avg 2 year Forecast
-$1.98
Avg 3 year Forecast
$2.79

INAB revenue forecast

What is INAB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$846.3k
Avg 3 year Forecast
$11.1M

INAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INAB$1.44$6.00+316.67%Buy
GTBP$0.45N/AN/A
QCLS$3.46N/AN/A
GNPX$1.54N/AN/A
CURX$0.49N/AN/A
View Top Biotech Stocks

In8bio Stock Forecast FAQ

Is In8bio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: INAB) stock is to Buy INAB stock.

Out of 1 analyst, 0 (0%) are recommending INAB as a Strong Buy, 1 (100%) are recommending INAB as a Buy, 0 (0%) are recommending INAB as a Hold, 0 (0%) are recommending INAB as a Sell, and 0 (0%) are recommending INAB as a Strong Sell.

If you're new to stock investing, here's how to buy In8bio stock.

What is INAB's earnings growth forecast for 2026-2028?

(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.

In8bio's earnings in 2026 is -$19,440,000.On average, 6 Wall Street analysts forecast INAB's earnings for 2026 to be -$17,275,733, with the lowest INAB earnings forecast at -$28,081,928, and the highest INAB earnings forecast at -$8,995,316. On average, 5 Wall Street analysts forecast INAB's earnings for 2027 to be -$19,485,420, with the lowest INAB earnings forecast at -$32,231,492, and the highest INAB earnings forecast at -$4,549,355.

In 2028, INAB is forecast to generate $27,453,684 in earnings, with the lowest earnings forecast at -$21,423,327 and the highest earnings forecast at $117,869,655.

What is INAB's revenue growth forecast for 2026-2028?

(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.

In8bio's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast INAB's revenue for 2026 to be $0, with the lowest INAB revenue forecast at $0, and the highest INAB revenue forecast at $0. On average, 6 Wall Street analysts forecast INAB's revenue for 2027 to be $8,334,035, with the lowest INAB revenue forecast at $0, and the highest INAB revenue forecast at $34,317,105.

In 2028, INAB is forecast to generate $109,292,841 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $337,528,670.

What is INAB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INAB) forecast ROA is -49.94%, which is lower than the forecast US Biotechnology industry average of 31.92%.

What is INAB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year INAB price target, the average INAB price target is $6.00, with the highest INAB stock price forecast at $6.00 and the lowest INAB stock price forecast at $6.00.

The Wall Street analyst predicted that In8bio's share price could reach $6.00 by Mar 13, 2027. The average In8bio stock price prediction forecasts a potential upside of 316.67% from the current INAB share price of $1.44.

What is INAB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INAB) In8bio's current Earnings Per Share (EPS) is -$4.44. On average, analysts forecast that INAB's EPS will be -$1.75 for 2026, with the lowest EPS forecast at -$2.85, and the highest EPS forecast at -$0.91. On average, analysts forecast that INAB's EPS will be -$1.98 for 2027, with the lowest EPS forecast at -$3.27, and the highest EPS forecast at -$0.46. In 2028, INAB's EPS is forecast to hit $2.79 (min: -$2.18, max: $11.97).

What is INAB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INAB) forecast ROE is -58.5%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.